Reduced expression of haloperidol conditioned catalepsy in rats by the dopamine D3 receptor antagonists nafadotride and NGB 2904.

Abstract

Haloperidol, a dopamine (DA) D2 receptor-preferring antagonist, produces catalepsy whereby animals maintain awkward posture for a period of time. Sub-threshold doses of haloperidol fail to produce catalepsy initially, however, when the drug is given repeatedly in the same test environment, gradual day-to-day increases in catalepsy are observed. More importantly, if sensitized rats are injected with saline instead of haloperidol they continue to be cataleptic in the test environment suggesting that environment-drug associations may play a role. DA D3 receptors have been implicated in a number of conditioned behaviors. We were interested if DA D3 receptors contribute to catalepsy sensitization and conditioning in rats. We tested this hypothesis using the DA D3 receptor-selective antagonist NGB 2904 (0.5, 1.8 mg/kg) and the DA D3 receptor-preferring antagonist nafadotride (0.1, 0.5 mg/kg). For 10 consecutive conditioning days rats were treated with one of the D3 receptor antagonists alone or in combination with haloperidol (0.25 mg/kg) and tested for catalepsy, quantified by the time a rat remained with its forepaws on a horizontal bar. On test day (day 11), rats were injected with saline or the D3 receptor antagonist and tested for conditioned catalepsy in the previously drug-paired environment. Rats treated with NGB 2904 or nafadotride alone did not develop catalepsy. Rats treated with haloperidol or haloperidol plus NGB 2904 or nafadotride developed catalepsy sensitization with repeated conditioning. When injected with saline they continued to exhibit catalepsy in the test environment--now conditioned. On the other hand, NGB 2904 (1.8 mg/kg) or nafadotride (0.5 mg/kg) given on the test day (after sensitization to haloperidol) significantly attenuated the expression of conditioned catalepsy. Our data suggest that the D3 receptor antagonist NGB 2904 (1.8 mg/kg) and nafadotride (0.5 mg/kg) significantly attenuate conditioned catalepsy in rats when given in test but not when given during sensitization. Results implicate DA D3 receptors in regulating the expression of conditioned catalepsy.

• Authors: Tomek J Banasikowski, Richard J Beninger
• Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (Eur Neuropsychopharmacol) Vol. 22 Issue 10 Pg. 761-8 (Oct 2012) ISSN: 1873-7862 [Electronic] Netherlands
• PMID: 22410316 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2012 Elsevier B.V. and ECNP. All rights reserved.

Chemical References

• Dopamine Antagonists
• Dopamine D2 Receptor Antagonists
• Fluorenes
• NGB 2904
• Naphthalenes
• Piperazines
• Pyrrolidines
• Receptors, Dopamine D3
• Haloperidol
• nafadotride

Topics

• Animals
• Behavior, Animal
• Catalepsy (chemically induced, drug therapy, prevention & control)
• Conditioning, Classical (drug effects)
• Disease Models, Animal
• Dopamine Antagonists (administration & dosage, therapeutic use)
• Dopamine D2 Receptor Antagonists
• Dose-Response Relationship, Drug
• Fluorenes (administration & dosage, therapeutic use)
• Haloperidol (administration & dosage)
• Male
• Motor Activity (drug effects)
• Naphthalenes (administration & dosage, therapeutic use)
• Piperazines (administration & dosage, therapeutic use)
• Pyrrolidines (administration & dosage, therapeutic use)
• Random Allocation
• Rats
• Rats, Wistar
• Reaction Time (drug effects)
• Receptors, Dopamine D3 (antagonists & inhibitors)
• Spatial Behavior (drug effects)
• Time Factors